Short News

Print

short news

 

PSIM Conference at
Swat from August 30th
to September 1st 2019

MINGORA (SWAT): Pakistan Society of Internal Medicine is holding its Mid-Summer Meeting at Swat in collaboration with Swat Medical College, Saidu Medical College, University of Health Sciences, King Edward Medical University, Nawaz Sharif Kidney Hospital and few other institutions. Updates in Internal Medicine is the theme of the conference. The conference is expected to be attended by a large number of physicians from all over the country.

The scientific committee has prepared a comprehensive programme for the three days conference. It includes Grand Rounds, interactive workshops, and scientific sessions. The local organizing committee is busy giving final touches to the final arrangements.


Preventing Recurrent Stroke
Dabigatran does not prove
better than Aspirin

Dabigatran is not superior to aspirin for preventing recurrent stroke in patients with recent history of embolic stroke of undetermined source, according to a study published in the May 16 issue of the New England Journal of Medicine.

Hans-Christoph Diener, M.D., Ph.D., from the University Duisburg-Essen in Germany, and colleagues conducted a multicenter, randomized, double-blind trial of dabigatran at 150 mg or 110 mg twice daily versus aspirin at 100 mg once daily among patients with embolic stroke of undetermined source. Data were included for 5,390 patients enrolled at 564 sites and randomly assigned to dabigatran (2,695 patients) or aspirin (2,695 patients).

The researchers found that recurrent strokes occurred in 6.6 and 7.7 percent of patients in the dabigatran and aspirin groups, respectively, during a median follow-up of 19 months (4.1 and 4.8 percent per year, respectively; hazard ratio, 0.85; 95 percent confidence interval, 0.69 to 1.03; P = 0.10). Ischemic strokes occurred at a rate of 4.0 and 4.7 percent per year, respectively (hazard ratio, 0.84; 95 percent confidence interval, 0.68 to 1.03). Major bleeding occurred at a rate of 1.7 and 1.4 percent per year, respectively (hazard ratio, 1.19; 95 percent confidence interval, 0.85 to 1.66).

“Post hoc analysis suggested that Dabigatran may have had an effect on stroke recurrence after one year, but no inferences can be made because of the post hoc nature of the analysis,” the authors write.

Note: Several authors disclosed financial ties to pharmaceutical companies, including Boehringer Ingelheim, which manufactures dabigatran and supported the study.

© Professional Medical Publications. All rights reserved.